Boehringer Ingelheim has inaugurated a state-of-the-art biopharmaceutical production facility in Vienna, Austria: representing the single largest investment in the company’s history.
The World Health Organization is recommending widespread use of the RTS,S/AS01 (RTS,S) vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
A probe has identified 'human error’ at the Spanish contract development and manufacturing organization, Rovi, as the reason for the presence of metal contaminants in Moderna COVID-19 vaccine doses, leading to Japanese authorities withdrawing 1.6...
VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.
M Ventures, the strategic, corporate venture capital arm of Merck KGgA, continues to fund iOmx Therapeutics AG, a company developing cancer therapeutics based on next generation immune checkpoint targets.
Marken, the clinical trial logistics subsidiary of UPS Healthcare, is adding significant capacity to support increased demand for its clinical drug supply chain services, particularly for cell and gene clinical trials.
The European Medicine Agency’s human medicines committee (CHMP) says that booster doses of the Pfizer/BioNTech vaccine may be considered in people aged 18+, although decisions on who is offered a booster will be made at a national level.
While several vaccines protect against meningitis, there remains an urgent need for innovation, funding and research to develop more meningitis-preventive vaccines, according to a new report from the WHO.
Moderna is investing in a 462,000 square foot building in Cambridge, Massachusetts, to create a purpose-built space for scientific research and development labs.
The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.
Fujifilm Irvine Scientific Inc has started the commissioning phase of its new 250,000 square feet (22,800 square meter) cell culture media manufacturing facility in Tilburg, the Netherlands; the site joins existing plants in the US and Japan.
CEOs at large pharma and biotech companies are upbeat when it comes to their outlook for both their own company and the industry at large; they also have a healthy appetite for M&A, found a KPMG survey.
AstraZeneca’s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a fibril-reactive monoclonal antibody (mAb) for the treatment of light chain (AL) amyloidosis.
Pfizer Inc has started a trial to evaluate its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.
Merck and Pfizer subsidiary, Wyeth LLC, have resolved a patent row related to their competing vaccines for preventing diseases including pneumonia and meningitis.
ViroCell Biologics and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) have formed a new partnership to immediately address the global viral vector manufacturing bottleneck for clinical trials
CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc., have enrolled the first participant in a Phase 1 clinical trial of their intranasal COVID-19 vaccine in Rochester, NY.
The biopharma industry continues to seek technologies that enable process control, while improving process development times and quality, says a Gamma Biosciences executive.
Takeda has received approval from Japan’s ministry of health to manufacture and market its stem cell therapy, Alofisel, for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD).
Open Pharma wants to see articles in peer-reviewed medical journals provide plain language summaries: those written in everyday language that is easy to understand by anyone from patients to policymakers. It's now set out its recommendations on how...
The US Food and Drug Administration (FDA) has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include a single booster dose in certain populations.
This month sees the launch of a new gene therapy player, Opus Genetics, a company backed and spun out by leading patient group Foundation Fighting Blindness’ venture arm, the Retinal Degeneration Fund (RD Fund).
AstraZeneca has announced a long-term research collaboration with VaxEquity for the discovery, development and commercialization of its self-amplifying RNA (saRNA) therapeutics platform.
Biocair has expanded its pharmaceutical and clinical trial logistics operations with new location in California, near Los Angeles International Airport.
Pfizer and BioNTech have released results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children aged 5 to 11 years old.
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.
AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.
Cytiva, in collaboration with China's Wego Pharmaceutical Co Ltd, is expanding manufacturing capacity for bioprocessing single-use consumables in China.
Johnson & Johnson says data published in The Lancet on its Ebola vaccine regimen shows it has a robust and durable immune response in adults and children.
French innovator, TreeFrog Therapeutics, which is focused on developing affordable stem cell-derived cell therapies, has just closed a US$75m (€64M) Series B financing round, bringing its total funding to date to US$83m (€70M).
CureVac is streamlining its external European manufacturing network for its mRNA product pipeline; having reassessed demand for its first-generation COVID-19 vaccine candidate.
3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).
The US medical research agency plans to offer funding over five years through a newly launched consortium, expected to include 30 sites across the country.
The UK government accuses Valneva of being in breach of its supply agreement obligations - something the company 'strenuously denies' - as it cancels its COVID-19 vaccine contract.
